EWTX Edgewise Therapeutics, Inc.
Healthcare$33.56+2.63%ClosedMarket Cap: $3.61B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
7.10
P/S
0.00
EV/EBITDA
-18.60
DCF Value
$0.50
FCF Yield
-4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.5%
ROA
-33.9%
ROIC
-40.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-54.1M | $-49.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-56.0M | $-50.2M | $— | — |
| FY null | $0.00 | -Infinity% | $-191.4M | $-167.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-46.9M | $-40.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-42.6M | $-36.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-46.0M | $-40.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-45.5M | $-39.7M | $— | — |
| FY null | $0.00 | NaN% | $-158.8M | $-133.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-40.4M | $-34.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-38.1M | $-31.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-34.8M | $-28.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-33.9M | $-30.1M | $-0.47 | — |